Arrowhead Research | ARWR - Operating Profit


Arrowhead Research reported $44.11M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Arrowhead Research USD 44.11M 209.66M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -260M 647M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025
Xencor USD -47.52M 14.35M Sep/2025